Key result
Zanthoxylum bungeanum extract reduces cholesterol and triglycerides by upregulating LDLR and RCT-related genes.
Variant pharmacological activities of Zanthoxylum bungeanum were determined before. The aim of this study was to assess whether Z. bungeanum could regulate lipid metabolism. The cholesterol overloading HepG2 cells induced by sterols were used as in vitro model to study lipid-lowering activities of the n-butanol (BuOH) fraction isolated from Z. bungeanum (ZBBu). Male apolipoprotein E knockout (apoE-KO) mice with high fat diet were used as in vivo model. We firstly demonstrated ZBBu had effects on reversed lipid accumulation, decreased apoB and enhanced apoA1 secretion. It increased the amount of low density lipoprotein receptor (LDLR) protein, also significantly inhibited the expression of SREBP-1 and SREBP-2's target molecule (hydroxy methylglutaryl coenzyme A reductase, HMGCR), which might be active in stimulation of RCT. And the expression of genes involved in RCT, such as CYP27A1, LXR-α, ABCG1, was promoted by ZBBu. Furthermore, ZBBu could reduce serum TC, TG levels in apoE-KO mice. Our study indicated that ZBBu could regulate the lipid metabolism through increasing the amount of low density lipoprotein receptor (LDLR) and inducing the expression of genes involved in RCT.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2014) studied Lipid metabolism / Dyslipidemia. Zanthoxylum bungeanum extract (ZBBu) was evaluated on Lipid metabolism markers (serum TC, TG, LDLR protein, and RCT-related gene expression). Zanthoxylum bungeanum extract reduced serum cholesterol and triglycerides in apoE-KO mice and regulated lipid metabolism by increasing LDLR and inducing RCT-related gene expression.
Synapse has enriched 5 related papers. Consider them for comparative context: